Durect

DURECT Corporation is an emerging specialty pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies to treat chronic debilitating diseases and enable biotechnology products. These platform technologies include the SABER™ Delivery System (a patented and versatile depot injectable useful for proteins, peptides and small molecule delivery), the ORADUR™ sustained release oral gel-cap technology (an oral sustained release technology with several potential abuse deterrent properties), the TRANSDUR™ transdermal patch technology, the DURIN™ Biodegradable Implant (drug-loaded implant system) and the MICRODUR™ Biodegradable Microparticulates (microspheres injectable system). DURECT also partners with pharmaceutical and biotechnology companies to develop and commercialize proprietary and enhanced pharmaceutical products based on its technologies. DURECT has five disclosed on-going development programs of which four are in collaboration with pharmaceutical partners. DURECT’s strategy is to capitalize on the wealth of opportunities afforded by our proprietary platform technologies in three ways: To internally develop promising products based on our technologies To partner some of our product opportunities with development and/or commercialization partners at appropriate stages along the development timelines; and To make our technologies, along with our pre-clinical and clinical development expertise available to partners with the desire to develop proprietary extended or controlled release formulations of a wide range of molecules.

Contact Details: 2 Results Way Cupertino CA 95014 United States of America Tel: 408.777.1417 Fax: 408 777 3577 Email: webmaster@durect.com WWW: www.durect.com/

Loading...

Recent Publications by Durect:
Pharmacokinetics of an implanted osmotic pump delivering sufentanil for the treatment of chronic pain. BACKGROUND: A matchstick-sized implanted osmotic pump (Chronogesic) that...	30th October, 2003	DURECT Corporation,	Anesthesiology. 2003 Oct;99(4):929-37.
Applications of continuous site-directed drug delivery. BACKGROUND: A matchstick-sized implanted osmotic pump (Chronogesic) that...	14th May, 2003	Department of Preclinical Research & Development, DURECT Corporation,	Proc West Pharmacol Soc. 2002;45:219-22.

Press Releases on Durect:
Neuropathic Pain Drug Market Will Increase From $6 Billion in 2008 to $9.7 Billion in 2018	16th November, 2009	Decision Resources	WALTHAM, Mass., Nov. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the neuropathic pain drug
Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook	10th November, 2009	Reportlinker	-- Profiles of key emerging drug delivery technologies and profiles of leading companies, by type of technology Who Should Buy This Report: -- Companies interested in understanding
Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech	6th October, 2009	Reportlinker	NEW YORK, Oct. 6 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and
FDA Accepts REMOXY New Drug Application and Grants Priority Review	12th August, 2008	King Pharmaceuticals, Inc.	SAN MATEO, Calif. and BRISTOL, Tenn., Aug. 12 /PRNewswire-FirstCall/ -- Pain Therapeutics, Inc. (Nasdaq: PTIE) and King Pharmaceuticals, Inc. (NYSE: KG) today announced that the New Drug Application
WWMR, Inc. Announces Launch of New Pain Clinic Monitor	4th June, 2008	WWMR, Inc.	SAN FRANCISCO, June 4 /PRNewswire/ -- Launch of the Pain Clinic Monitor, a new audit of Pain Clinics, was announced today by WWMR, Inc. a leader in pain reporting and analysis. First quarter 2008

BioNews Results for Durect:
Durect Q3 net loss narrows	Individual.com:  Oct 30 2009 1:28PM Matching: durect
DURECT Corporation Announces Third Quarter 2009 Financial Results	Individual.com:  Oct 29 2009 10:53PM Matching: durect
DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call	Pharma Live:  Oct 27 2009 1:42AM Matching: durect
DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call	Montana's News Station:  Oct 27 2009 7:12AM Matching: durect
DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call	Freshnews.com:  Oct 27 2009 4:32AM Matching: durect
Promote your company here: BioNewsCast - Press Release Distribution	→View more Durect news.

Durect Clinical Trials:
A Safety and Efficacy Study of SABER™-Bupivacaine for Pain Following Hernia Repair

Durect Patents:
US Patent No.	Title
7589110	Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
6685697	Controlled release system for delivering therapeutic agents into the inner ear
6648873	Aural catheter system including anchor balloon and balloon inflation device
6638263	Regulation of drug delivery through flow diversion
6629969	Catheter for modification of agent formulation
→View more Durect patents.

Durect (DRRX) Financial information Links from Barchart
DRRX Quote from from Barchart.com
DRRX Chart from from Barchart.com
DRRX Profile from from Barchart.com
DRRX Opinion from from Barchart.com
→View more Durect finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 327 times since April 2007, the link to the organisation's website has been followed 63 times

Recent Search Terms used to find this page: osmotic pump patent - inner ear - drugs | patent ORADUR sustained released oral gel-cap technology | .

Search for more companies in Cupertino

Search for more companies in CA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Durect